Medtronic Defends Endeavor DES Late Loss, Questions Clinical Relevance

The relatively high rates of late lumen loss in Medtronic's ENDEAVOR-I drug-eluting stent trial can be traced to the large reference vessel size of the study subjects, according to Harvard Medical School's Richard Kuntz, MD